Part II: NP/PA 16-Hour Waiver Training
Recorded On: 12/10/2015
The 16-hour product developed includes all additional education required by the Comprehensive Addiction and Recovery Act (CARA) for nurse practitioners to successfully apply for a waiver to prescribe buprenorphine for office-based treatment of opioid use disorders.
Click the "Content" tab to get started!
Tricia Wright
MD, MS, FACOG, FASAM
Tricia Wright, MD MS is an assistant professor of Obstetrics, Gynecology and Women's Health at the University of Hawaii John A. Burns School of Medicine and founder, former medical director, and now Women's Health Liaison of the PATH Clinic, an outreach clinic of Waikiki Health Center, which provides prenatal, postpartum and family planning to women with a history of substance use disorders. She is board certified in both Ob/Gyn and Addiction Medicine and a Fellow of the American College of Obstetrics and Gynecology. She has been waivered to provide buprenorphine since 2009, and has treated both pregnant and non-pregnant women. She won funding approval in 2006 from the Hawaii legislature to start a perinatal clinic for women with substance use, the first in the state. The Path Clinic opened in 2007, and has seen over 400 pregnant women since that time. She completed her Masters Degree in Clinical Research from the University of Hawaii in 2009, her thesis paper studying the disparities of smoking and drug use rates during pregnancy of Native Hawaiian women. Her research interests include substance use disorders among pregnant women, including barriers to family planning, screening, brief intervention and referral to treatment (SBIRT), best practices for treatment, and the effects of methamphetamine, marijuana and tobacco on the placenta.
Timothy K. Brennan
MD, MPH
Timothy Brennan, MD, MPH is an Addiction Medicine physician and Pediatrician. He is the Director of the Fellowship in Addiction Medicine at the Addiction Institute of New York at Mount Sinai Roosevelt Hospital. He completed a Fellowship in Addiction Medicine at the Addiction Institute of New York, a Fellowship in Medical Ethics at Harvard Medical School, a Residency in Pediatrics at Weill Cornell Medical College / New York Presbyterian Hospital, and an Internship in Internal Medicine at Georgetown University Hospital. He is the Co-Editor of Essentials of Addiction Medicine. He is Board Certified in Addiction Medicine and Pediatrics.
Brian Hurley
MD, MBA, DFASAM
Brian Hurley, MD, MBA is a Veterans Administration National Quality Scholar affiliated with the University of California, Los Angeles (UCLA) at the VA Greater Los Angeles Healthcare System, and will be a 2015-2017 Robert Wood Johnson Foundation Clinical Scholar at UCLA. He completed a fellowship program in addiction psychiatry at New York University School of Medicine. He completed residency training at the Massachusetts General Hospital and McLean Hospital (MGH-McLean), where he was Chief Resident in Addiction Psychiatry. Brian applied to medical school with the explicit intention of becoming an addiction physician. He joined ASAM in 2002 as a first year medical student, and has served on the ASAM Board of Directors in various capacities since 2003. He currently serves as the co-chair of ASAM's Membership Committee and serves on ASAM's Finance Committee. He previously served as chair of ASAM's Physicians-in-Training Committee Chair and is formerly ASAM's alternate delegate to the American Medical Association. Brian additionally served on the EVP/CEO search committee in 2010 that led to Penny Mill's selection as ASAM's current EVP/CEO. He has additional served in various roles for the Massachusetts Society of Addiction Medicine, New York Society of Addiction Medicine, and California Society of Addiction Medicine. Aside from ASAM, Brian is a former National President of the American Medical Student Association. He is a 2012 American College of Psychiatrists Laughlin fellow, a 2010-2013 American Psychiatric Association (APA) Public Psychiatry Fellow, and a 2015-2017 Group for Advancement of Psychiatry Fellow. Brian also serves on the American Medical Colleges' Advisory Committee on Sexual Orientation, Gender Identity, and Sex Development. He is also the Gay and Lesbian Medical Association's delegate to the American Medical Association's (AMA's) House of Delegates. Brian has previously served on the Board of Trustees of the APA.
The collaborative of ASAM, AANP and AAPA identified and reviewed this content to provide the NP/PA training required by CARA.
The NP/PA 24-Hour Waiver Training is available for free through 2017 in part by an unrestricted educational grant from Indivior.
The 16-hour product developed includes all additional education required by the Comprehensive Addiction and Recovery Act (CARA) for nurse practitioners to successfully apply for a waiver to prescribe buprenorphine for office-based treatment of opioid use disorders.
Download this helpful FAQ for technical issues.
All other questions, contact ASAM Education.
education@ASAM.org | 301.656.3920
Upon successful completion of all 16 hours, return to the AANP CE Center to submit an evaluation and claim credit.
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.
Apply
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Qualify
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider or through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, supervision or working in collaboration with a qualifying physician (physician must be waivered) to prescribe medications for the treatment of OUD may be required.